Background: Transfemoral transcatheter aortic valve replacement (TAVR) was superior to surgical
| I N TR ODU C TI ON
Transcatheter aortic valve replacement (TAVR) is currently approved as an alternative to surgical aortic valve replacement (SAVR) in high-risk or inoperable patients with severe, symptomatic aortic stenosis (AS) [1, 2] . Recent data from the placement of aortic transcatheter valves (PARTNER) 2A trial (P2), and a propensity-matched Sapien 3 registry, showed that transfemoral TAVR is superior to SAVR in intermediate-risk patients [3, 4] . Based on these two trials, the Food and Drug The implications of expanding indications of TAVR to intermediate-risk patients could be considerable to the U.S. healthcare system. First, census projections estimate 88.5 million Americans will be over the age of 65 by 2050 [5] . The most common form of AS is age-related or degenerative form [6] . Therefore, the incidence of severe AS that requires treatment is likely to increase [7] . Second, of the 141,905 isolated SAVR procedures reported in the Society of Thoracic Surgeons (STS) database in the last decade approximately 20,000 (14%) were performed in intermediate-risk patients [8] . Although the number of TAVR programs in the US is proliferating, from 228 in 2012 to 348 in 2014, they still represent a small fraction of the more than 1,000 existing surgical programs that report outcomes to the STS database [9] . Therefore, with the expansion of indications of TAVR a surge in the number of new TAVR programs may be expected. Finally, for existing TAVR programs expanding the procedure indications to intermediate risk patients will require additional resources, which will require advance planning and budgeting. In this retrospective analysis, baseline characteristics and outcomes of intermediate-risk patients undergoing TAVR and SAVR at the MVAHCS were compared after ensuring that both programs had comparable outcomes relative to STS database (for SAVR) and pivotal TAVR trials with balloon-expandable valves (for TAVR and SAVR) ( Figure 1 ).
| Patient selection 2.2.1 | Savr
We included all patients undergoing SAVR, with or without concomi- which have resulted in improved outcomes [8] . We excluded patients that were unlikely to become TAVR candidates due to non-aortic pathology that required surgical correction. These included (1) patients undergoing complex operations (AVR plus great vessel surgery, double valve replacement or other complex surgical procedures) and (2) significant (>50%) left main coronary artery disease.
| Tavr
We included all patients undergoing TAVR at our institution, irrespec- 
| Outcome
The primary outcome of the study was the incidence of death or stroke 30-days after aortic valve replacement, either surgical or transcatheter.
Secondary outcomes were 30-day post-procedure mortality and hospital length of stay.
| External comparison groups
First, two surgical control groups were selected to ensure that VA surgical outcomes were comparable to those obtained in the private 
| Estimation of perioperative mortality
The risk of perioperative mortality was estimated by the Veterans Administration (VA) risk score. Since 1987, data from all patients undergoing cardiac surgery VA medical centers have been collected as part of a quality improvement program [11] . This ongoing, prospective database includes demographic information, preoperative clinical variables, surgical details, and postoperative outcomes including 30-day mortality and major complications. The database also includes a validated risk score, which measures patient risk at the time of cardiac surgery on a scale that ranges from 0% to 100%, with the higher numbers indicating greater risk [12, 13] . This score is calculated by multivariable logistic regression analysis, where the variables with P < 0.2 in univariable analysis are included in the multivariable logistic regression model. Twice each year, statistical analyses are done to assess the performance of each cardiac surgical center and to recalibrate the regression models that predict operative mortality. We have previously shown that the STS and VA risk score have good calibration and discrimination in this population [14] . For this analysis, patients in whom the VA risk score predicted a mortality risk <4% at 30-days were considered low risk, 4%-8% intermediate risk, and >8% high risk. The mean EF was 49% (612). The majority of TAVR procedures were done using transfemoral access (85%) and balloon-expandable valves 
| Statistical analysis

| RE S U L TS
| TAVR versus SAVR real-world comparison
The outcomes of intermediate-risk patients treated with SAVR and TAVR at the MVAHCS are presented in Table 4 and Figure 3 . Despite older age (80 6 7 vs. 74 6 9, P < 0.001) and a higher incidence of previous heart surgery (34% vs. 13%, P 5 0.001) in the TAVR cohort, periprocedural mortality (0% vs. 7%, P 5 0.07) and the composite of death or stroke at 30-days was significantly lower with TAVR relative to SAVR (2.2% vs. 12%, P 5 0.05). Similarly, length of stay was shorter with TAVR (4 vs. 10 days, P 5 0.01). The number needed to treat to 
| Comparison of TAVR groups
A comparison of TAVR groups in key baseline characteristics and outcomes is presented in the Supporting Information, Appendix Table 3 .
Despite some differences in baseline characteristics, both cohorts had similar 30-day predicted mortality. The observed combined rate of stroke or death at 30-days was significantly lower than predicted for both groups treated with TAVR (MVAHCS: 2.2% vs. S3 registry: 2%, P 5 0.92).
| D ISC USSION
Using a contemporary cohort of patients with severe AS and intermediate surgical risk we found that TAVR offers a quantifiable improvement and had one of the lowest surgical mortality rates (1.7%) ever reported in randomized surgical studies [3, 4, 17] . Thus, TAVR had similar outcomes to SAVR even when compared to a "best case scenario" surgical comparison group. However, these excellent surgical results may not be generalizable to the real world. The 30-day surgical mortality for and permanent pacemaker implantation than SAVR [2] [3] [4] 17] . In a previous study we showed that 6% of SAVR patients require a pacemaker implantation in the perioperative period [20] , which is in line with the P2 trial. The incidence of moderate-severe paravalvular regurgitation (1.3%) appears to be decreasing with technological improvements such as a sealing skirt at the lower portion of the stent frame [4] . In contrast, and probably related to the presence of the "skirt", the incidence of PPM is increasing (12%) [9] . 
